Zobrazeno 1 - 10 of 2 214 pro vyhledávání: '"Kneitz B"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Metformin Regulates the miR-205/VEGFA Axis in Renal Cell Carcinoma Cells: Exploring a Clinical Synergism with Tyrosine Kinase Inhibitors.
Autor: Krebs M; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany., Kotlyar MJ; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany, mischa.kotlyar@gmail.com.; Department of Interdisciplinary Critical Care Medicine and Intermediate Care, Helios Clinic Erfurt, Erfurt, Germany, mischa.kotlyar@gmail.com., Fahl J; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany., Janaki Raman S; Chair of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, Würzburg, Germany., Röhrig F; Chair of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, Würzburg, Germany., Marquardt A; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Institute of Pathology, Klinikum Stuttgart, Stuttgart, Germany., Kübler H; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany., Kneitz B; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany., Schulze A; Chair of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, Würzburg, Germany.; Division of Tumor Metabolism and Microenvironment, German Cancer Research Center, Heidelberg, Germany., Kalogirou C; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Publikováno v: Urologia internationalis [Urol Int] 2024; Vol. 108 (1), pp. 49-59. Date of Electronic Publication: 2023 Nov 30.
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis
Autor: Kalogirou, C., Ellinger, J., Kristiansen, G., Hatzichristodoulou, G., Kübler, H., Kneitz, B., Busch, J., Fendler, A.
BACKGROUND: Expression of circulating serum microRNAs has not been studied in a cohort of patients with papillary renal cell carcinoma (pRCC) so far. We hypothesized that miRNA deregulation in malignant tissue is reflected in serum and could be used
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=mdc______med::7ea6ab93835b163e4406800ee14f277d
http://edoc.mdc-berlin.de/19136/1/19136oa.pdf
Zobrazit plný text záznamu
5
Akademický článek
Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava.
Autor: Kotlyar MJ; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany., Krebs M; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany., Solimando AG; Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, Aldo Moro University of Bari, 70124 Bari, Italy.; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, 70124 Bari, Italy., Marquardt A; Department of Pathology, Klinikum Stuttgart, 70174 Stuttgart, Germany., Burger M; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany., Kübler H; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany., Bargou R; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany., Kneitz S; Physiological Chemistry I, Theodor-Boveri-Institute, Biocenter, University of Würzburg, 97074 Würzburg, Germany., Otto W; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany., Breyer J; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany., Vergho DC; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany., Kneitz B; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany., Kalogirou C; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Publikováno v: Cancers [Cancers (Basel)] 2023 Mar 26; Vol. 15 (7). Date of Electronic Publication: 2023 Mar 26.
Zobrazit plný text záznamu
6
Akademický článek
O23 - Squalene epoxidase, an easily druggable target in urothelial cancer
Autor: Schmucker, P., Eckstein, M., Kneitz, B., Kübler, H., Kalogirou, C.
Publikováno v: In European Urology Open Science October 2022 44 Supplement 2:S174-S174
Zobrazit plný text záznamu
7
Akademický článek
Ki-67, topoisomerase IIα and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohort.
Autor: Marra G; Department of Urology and Department of Pathology, Institut Mutualiste Montsouris, Paris, France.; Department of Surgical Sciences, University of Turin and San Giovanni Battista Hospital, Città della Salute e della Scienza, Turin, Italy., Oderda M; Department of Surgical Sciences, University of Turin and San Giovanni Battista Hospital, Città della Salute e della Scienza, Turin, Italy., Calleris G; Department of Surgical Sciences, University of Turin and San Giovanni Battista Hospital, Città della Salute e della Scienza, Turin, Italy., Marquis A; Department of Surgical Sciences, University of Turin and San Giovanni Battista Hospital, Città della Salute e della Scienza, Turin, Italy., Peretti F; Department of Surgical Sciences, University of Turin and San Giovanni Battista Hospital, Città della Salute e della Scienza, Turin, Italy., Zitella A; Department of Surgical Sciences, University of Turin and San Giovanni Battista Hospital, Città della Salute e della Scienza, Turin, Italy., Moschini M; Department of Urology and Department of Pathology, Institut Mutualiste Montsouris, Paris, France., Sanchez-Salas R; Department of Urology and Department of Pathology, Institut Mutualiste Montsouris, Paris, France., Karnes RJ; Department of Urology, Mayo Clinic, Rochester, MN, USA., Kneitz B; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany., Spahn M; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany., Pacchioni D; Department of Pathology, University of Turin and San Giovanni Battista Hospital, Città della Salute e della Scienza, Turin, Italy., Gontero P; Department of Surgical Sciences, University of Turin and San Giovanni Battista Hospital, Città della Salute e della Scienza, Turin, Italy.
Publikováno v: Translational andrology and urology [Transl Androl Urol] 2022 Sep; Vol. 11 (9), pp. 1271-1281.
Zobrazit plný text záznamu
8
Akademický článek
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer.
Autor: Eckhardt C; University Hospital Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetology, Würzburg, Germany., Sbiera I; University Hospital Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetology, Würzburg, Germany., Krebs M; University Hospital Würzburg, Department of Urology and Pediatric Urology, Würzburg, Germany.; University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Sbiera S; University Hospital Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetology, Würzburg, Germany., Spahn M; Lindenhofspital, Bern, Switzerland.; Department of Urology, University Hospital Essen, Essen, Germany., Kneitz B; University Hospital Würzburg, Department of Urology and Pediatric Urology, Würzburg, Germany., Joniau S; Department of Urology, University Hospitals Leuven, Leuven, Belgium., Fassnacht M; University Hospital Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetology, Würzburg, Germany.; University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Kübler H; University Hospital Würzburg, Department of Urology and Pediatric Urology, Würzburg, Germany.; University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Weigand I; University Hospital Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetology, Würzburg, Germany.; Department of Medicine IV, University Hospital Munich, Ludwig-Maximilians-Universität München, München, Germany., Kroiss M; University Hospital Würzburg, Department of Internal Medicine I, Division of Endocrinology and Diabetology, Würzburg, Germany. Kroiss_M@ukw.de.; University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany. Kroiss_M@ukw.de.; Department of Medicine IV, University Hospital Munich, Ludwig-Maximilians-Universität München, München, Germany. Kroiss_M@ukw.de.
Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2022 Sep; Vol. 25 (3), pp. 484-490. Date of Electronic Publication: 2021 Jul 29.
Zobrazit plný text záznamu
9
miR-221 als Regulator der Expression von VEGFR2 in Prostatakarzinomzellen und als potentieller Prädiktor eines anti-angiogenen Therapieerfolgs
Autor: Krebs, M, Kalogirou, C, Sokolakis, I, Vergho, D, Spahn, M, Kübler, H, Riedmiller, H, Kneitz, B
Publikováno v: 43. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung; 20170518-20170520; Wien; DOC17oegu004 /20170403/
Hintergrund: Bisherige klinische Studien zur anti-angiogenen Therapie von Prostatakarzinom (PCa)-Patienten zeigten keine durchschlagenden Erfolge. Angesichts der Heterogenität des PCa könnte dieser Umstand durch Biomarker gemildert werden, die den
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::387369129bac2305e7cc5c704f946e3e
Zobrazit plný text záznamu
10
Pretreatment tables predicting pathologic stage of locally advanced prostate cancer
Autor: Joniau, S, Spahn, M, Briganti, A, Gandaglia, G, Tombal, B, Tosco, L, Marchioro, G, Hsu, Cy, Walz, J, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, van Cangh, P, Karnes, Rj, Montorsi, F, van Poppel, H, Gontero, Paolo, European Multicenter Prostate Cancer Clinical, Translational Research Group
Background Pretreatment tables for the prediction of pathologic stage have been published and validated for localized prostate cancer (PCa). No such tables are available for locally advanced (cT3a) PCa. Objective To construct tables predicting pathol
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c6962dde787e4044b4a62a650cd5237
http://hdl.handle.net/2318/156718
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje